The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Novavax. The chart below shows the ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Shares of Novavax Inc. NVAX slid 3.09% to $7.83 Wednesday, on what proved to be an all-around mixed trading session for the ...

Spire Wealth Management bought a new position in Novavax, Inc. (NASDAQ:NVAX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs says the company is at a pivot point.

Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...